SQ-LIP-000022 · v1.1 (archived) · View current version →

What clinical criteria and stage/type classification systems are used to diagnose and grade lipedema, and how reliable are they?

Knowledge freshness = share of the 9 indexed evidence sources from the last 5 years (newest 2025, oldest 2012) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.

What changed in this version

This update built the answer from scratch, establishing that lipedema diagnosis is clinically based with recognized criteria and stage/type systems, and registering converging moderate-grade evidence that clinical criteria discriminate well (AUC 0.86–0.91; CART 100%) while morphological staging is unreliable as a severity measure and objective adjunct tools remain inadequately validated.

Supporting claims

• SCR-LIP-000190 supporting
  In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using three clinical variables—bruising, body disproportion, and non-swollen feet (cuffing sign)—classified patients with 100% accuracy; lipedema was characterized by symmetry (100%), spared feet (93.5%), pain (92%), bruising (90.6%), telangiectasias (89.9%), and family history (84.7%), and staged 1-4 (stage I 37.7%, II 34.8%, III 22.5%, IV 5.1%).
  Building evidence for diagnosis of lipedema: using a classification and regression tree (CART) algorithm to differentiate lipedema from lymphedema patients — FORNER-CORDERO et al. (2025)
• SCR-LIP-000194 supporting
  This systematic review describes lipedema diagnosis as primarily clinical and outlines a 3-stage clinical staging system (Stage I normal skin with small palpable nodules; Stage II irregular surface with liposclerosis; Stage III lobular deformation with peau d'orange) plus Schingale's 5-type classification (I hips/thighs, II to knees, III to ankles, IV arms+legs, V lipo-lymphedema), with key differential signs (negative Stemmer, foot dorsum sparing) and noncontrast CT reported at 95% sensitivity and 100% specificity.
  Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review — Forner‐Cordero et al. (2012)

Contradictory claims

• None indexed yet.

Refining / context

• SCR-LIP-000187 refines
  In a study comparing lipedema patients to healthy controls, DXA body composition analysis showed the leg fat mass/total fat mass index achieved AUC=0.90 (sensitivity 0.95, specificity 0.73, cutoff 0.383) and was the only index to differentiate cases from controls across all BMI strata, but FM indices showed no significant correlation with disease stage, indicating they reflect the pathognomonic fat distribution rather than clinical progression; the study notes diagnosis is currently based almost exclusively on clinical criteria that may be subjective and not always reliable.
  Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema — Buso et al. (2022)
• SCR-LIP-000188 refines
  A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328).
  Criação de questionário e modelo de rastreamento de lipedema — Amato et al. (2020)
• SCR-LIP-000189 context
  In a prospective cohort of 83 women diagnosed with lipedema using clinical criteria, lipedema was classified by clinical stage (most often stage 1, 39.8%) and type (most often type III, hips to ankles, 74.7%), and lymphoscintigraphic abnormality grade showed no significant association with clinical stage (p=0.142), type (p=0.505), Stemmer's sign (p=0.506), age, or BMI.
  Hallazgos linfogammagráficos en pacientes con lipedema — Forner-Cordero et al. (2018)
• SCR-LIP-000191 refines
  Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging.
  Lipedema and Dercum's Disease: A New Application of Bioimpedance — Crescenzi et al. (2019)
• SCR-LIP-000192 refines
  This systematic review of molecular and cellular lipedema studies argues that the current staging system based on Wold (1951) is insufficient for the disease's clinical heterogeneity and proposes its revision to incorporate comorbidities (obesity, lymphedema), pre-surgical weight, and family history.
  Lipedema Research—Quo Vadis? — Ernst et al. (2023)
• SCR-LIP-000193 refines
  The S2k lipedema guideline defines lipedema as painful, disproportionate, symmetrical adipose distribution occurring almost exclusively in women, and states that diagnosis is clinical, requiring disproportion plus concomitant symptoms (pain), while morphological staging should NOT be used as a measure of severity, the 'nodular' criterion should not be used for diagnosis, and no instrument (duplex, ultrasound, MRI, lymphoscintigraphy, laboratory tests) can confirm lipedema (they serve only for differential diagnosis).
  S2k guideline lipedema — Faerber et al. (2024)
• SCR-LIP-000195 refines
  A systematic review of 13 assessment tools (8 imaging, 5 clinical measurement) for quantifying lipedema limbs found highly heterogeneous and poorly documented protocols, with clinimetric reliability reported in only 2 studies: tissue dielectric constant showed high interrater reliability at the distal leg and ankle (ICC 0.935–0.937) but low at the foot dorsum (ICC 0.633), and MR/NCMRL showed only fair-to-slight interradiologist agreement (Kappa 0.14–0.34); DXA fat-distribution indices (AUC 0.91) and pretibial ultrasound subcutaneous thickness (cutoffs 11.6–11.8 mm, sensitivity 0.77–0.79, specificity 0.92–0.96) reported diagnostic performance.
  Assessment Tools to Quantify the Physical Aspects of Lipedema: A Systematic Review — Eason et al. (2025)

Major uncertainty

The reliability of the staging/type systems themselves remains poorly established and contested. There is no high-grade (RCT/meta-analytic) evidence on inter-rater reliability of clinical staging, and the indexed sources—mostly cross-sectional studies, cohorts, and consensus reviews of moderate-to-low grade—converge on the view that morphological staging does not track disease severity and may be subjective. While clinical criteria discriminate lipedema from lymphedema/controls well in single studies, no validated, universally adopted diagnostic criteria set or reliability standard exists, objective adjunct tools lack clinimetric validation, and classification systems (Wold-based staging, type schemes) are heterogeneously applied across studies, limiting comparability.

Version history

• SQ-LIP-000022 · v1.1 — 2026-05-31 — This update built the answer from scratch, establishing that lipedema diagnosis is clinically based with recognized criteria and stage/type systems, and registering converging moderate-grade evidence that clinical criteria discriminate well (AUC 0.86–0.91; CART 100%) while morphological staging is unreliable as a severity measure and objective adjunct tools remain inadequately validated. · view this version
• SQ-LIP-000022 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000003). · view this version

Key references

DOI:10.1159/000527138 · DOI:10.1590/1677-5449.200114 · DOI:10.1016/j.remn.2018.06.008 · DOI:10.23736/s0392-9590.25.05207-1 · DOI:10.1089/lrb.2019.0011 · DOI:10.3390/jpm13010098 · DOI:10.1111/ddg.15513 · DOI:10.1111/j.1758-8111.2012.00045.x · DOI:10.1089/lrb.2024.0102

← All questions